Dr. Howard Smith Oncall

Vidcast:  https://www.instagram.com/p/C1A0Gw-r5fJ/ That’s the promise of a new long-acting form of GLP-1 agonist diet drugs developed by bioengineering material science researchers at Stanford University.  Placing a larger dose of the drug in a hydrogel depot permits its slow release over an extended period as long as 4 months.  This long-acting drug formulation not only benefits those fighting obesity but type 2 diabetics as well. One shot delivers medication over the time that normally requires 42 separate shots.  At this time, this system has only been tested in rats, but human trials are expected to begin with several years.  Once those are completed, this more convenient dosing alternative could reach you…..someday soon. https://www.cell.com/cell-reports-medicine/fulltext/S2666-3791(23)00486-X #semaglutide #depot #extendedrelease #obesity #diabetes